Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eleanor Malone
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta and Anoro Ellipta support the product's ability to reduce exacerbations in more severe COPD. However, the benefit of IMPACT in expanding GSK's respiratory sales may be limited given pricing pressures and the make-up of GSK's current portfolio.
With the FDA approval of Trelegy Ellipta, GlaxoSmithKline will enjoy first-to-market status with a LABA/LAMA/ICS triple combination therapy to treat COPD in the US. However, it faces the challenge of convincing payers.
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
In 2016, the 15 top pharma companies paid their CEOs $276m in total* while those same firms reported a total net income of $96.5bn**. Altogether these companies had a market capitalization of $2,238bn on June 30, 2017**. In this infographic Scrip gives a snapshot of these companies' leaders and the businesses they oversee.
Commercial Capsules: Autoimmune Positioning; Sanofi In China; Migraine Race; BMS Deal; Clinical Advances
AbbVie outlines how it will stay top dog in autoimmune therapy; Dermira licenses lebrikizumab, threatening pressure on Sanofi/Regeneron's Dupixent; Sanofi has driven up vaccine sales in China after responding to new government distribution rules; Lilly plans a migraine filing; FibroGen, Myokardia and Hansa Medical advance in the clinic and Bristol-Myers shells out up to $2.3bn to turn cold tumors hot. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
Pfizer's CEO says uncertainty over US tax reform was staying his hand in M&A; following AstraZeneca's MYSTIC miss, Bristol-Myers Squibb and Merck & Co. were duly grilled over their own PD-1/CTLA-4 combination programs; recent deals highlight gathering enthusiasm for combining PARP and PD-1/PD-L1 inhibition. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.